Inhibrx Biosciences(NASDAQ) INBX

Inhibrx Biosciences, Inc. treats rare and difficult cancers. New drugs help the immune system kill tumor cells. The products help patients with few other medical options.

Fighting Cancer With Better Proteins

• Ozekibart: A tetravalent agonist designed to trigger cell death in solid tumors; currently being evaluated in clinical trials for colorectal cancer and chondrosarcoma.
• INBRX-106: A hexavalent agonist that stimulates the immune system to fight tumors; tested in combination with other treatments for lung, head, and neck cancers.
• Protein Platforms: Modular engineering tools used to build complex biologic candidates; these systems allow scientists to optimize how a drug binds to a target.

Moving Toward Regulatory Approval

• Announced that ozekibart met its primary goal in a trial for chondrosarcoma in October 2025, more than doubling the time patients lived without disease progression.
• Submitted a biologics license application (a request for permission to sell a new biological product) to the U.S. Food and Drug Administration in June 2026.
• Initiated two additional Phase 1 clinical trial cohorts for colorectal cancer treatments during the second quarter of 2026.
• Secured an amendment to its loan agreement in July 2026 that provides access to up to $325 million in new capital.

Engineering Specific Immune Responses

Inhibrx creates therapeutic candidates with precise valency, which refers to the number of binding sites on a molecule. This approach allows the company to optimize how its drugs activate the immune system for specific targets.

Financial Reality of Drug Development

• Net loss was $36.7 million for the quarter ended June 30, 2026, widening 28% year over year.
• Research and development spending reached $23.9 million in the second quarter of 2026, up 7% year over year.
• The company held $133.3 million in cash and cash equivalents as of June 30, 2026.
• License fee revenue fell to zero for the three months ended June 30, 2026, down 100% year over year.
• Total accumulated deficit was $316.3 million as of June 30, 2026.

Evolution From Lab to License

Inhibrx has transitioned from early-stage research to the clinical development and regulatory filing phase for its lead cancer treatments. The company relies on debt and equity financing to support its pipeline as it seeks its first commercial approval.